Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 329

1.

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2018 Jun 8. doi: 10.1093/rheumatology/key151. [Epub ahead of print]

PMID:
29893938
2.

Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design.

Hughes M, Tracey A, Bhushan M, Chakravarty K, Denton CP, Dubey S, Guiducci S, Muir L, Ong V, Parker L, Pauling JD, Prabu A, Rogers C, Roberts C, Herrick AL.

J Scleroderma Relat Disord. 2018 Jun 1;3(2):170-174. doi: 10.1177/2397198318764796. Epub 2018 Mar 27.

3.

Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?

Hughes M, Murray A, Denton CP, Herrick AL.

Med Hypotheses. 2018 Jul;116:101-104. doi: 10.1016/j.mehy.2018.04.024. Epub 2018 May 2.

PMID:
29857890
4.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 May 31. pii: annrheumdis-2018-213031. doi: 10.1136/annrheumdis-2018-213031. [Epub ahead of print]

5.

Smoking in Systemic Sclerosis: a Longitudinal European Scleroderma Trials and Research Group Study.

Jaeger VK, Valentini G, Hachulla E, Cozzi F, Distler O, Airó P, Czirják L, Allanore Y, Siegert E, Rosato E, Matucci-Cerinic M, Caimmi C, Henes J, Carreira PE, Smith V, Del Galdo F, Denton CP, Ullman S, Langhe E, Riccieri V, Alegre-Sancho JJ, Rednic S, Müller-Ladner U, Walker UA; EUSTAR co-authors.

Arthritis Rheumatol. 2018 May 21. doi: 10.1002/art.40557. [Epub ahead of print]

PMID:
29781588
6.

Double-blind, Randomized, 8-week Placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2018 May 6. doi: 10.1002/art.40547. [Epub ahead of print]

PMID:
29732731
7.

Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.

Bageghni SA, Hemmings KE, Zava N, Denton CP, Porter KE, Ainscough JFX, Drinkhill MJ, Turner NA.

FASEB J. 2018 Mar 30:fj201701455RR. doi: 10.1096/fj.201701455RR. [Epub ahead of print]

PMID:
29601781
8.

Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.

Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, Marra AM, Benjamin N, Fischer C, Grünig E.

Eur Respir J. 2018 Apr 4;51(4). pii: 1701197. doi: 10.1183/13993003.01197-2017. Print 2018 Apr.

PMID:
29563168
9.

The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.

Dhaliwal K, Griffin M, Denton CP, Butler PEM.

BMJ Case Rep. 2018 Mar 9;2018. pii: bcr-2017-219348. doi: 10.1136/bcr-2017-219348.

PMID:
29525756
10.

Reply.

Denton CP, Herrick AL.

Arthritis Rheumatol. 2018 Jun;70(6):974. doi: 10.1002/art.40480. Epub 2018 May 2. No abstract available.

PMID:
29513930
11.

Autologous fat transfer in the successful treatment of upper limb linear morphoea.

Mura S, Fin A, Parodi PC, Denton CP, Howell KJ, Rampino Cordaro E.

Clin Exp Rheumatol. 2018 Feb 14. [Epub ahead of print] No abstract available.

PMID:
29465364
12.

Development of systemic sclerosis in transgender females: a case series and review of the literature.

Campochiaro C, Host LV, Ong VH, Denton CP.

Clin Exp Rheumatol. 2018 Feb 19. [Epub ahead of print]

PMID:
29465362
13.

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon.

Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME, Britton J, Buch MH, Del Galdo F, Denton CP, Dinsdale G, Griffiths B, Hall F, Howell K, MacDonald A, McHugh NJ, Manning JB, Pauling JD, Roberts C, Shipley JA, Herrick AL, Murray AK.

Arthritis Rheumatol. 2018 Jun;70(6):903-911. doi: 10.1002/art.40457. Epub 2018 Apr 23.

14.

Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis.

Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, Davies S, de Oliveira Pena J, Khanna D.

Rheumatology (Oxford). 2018 May 1;57(5):813-817. doi: 10.1093/rheumatology/kex504.

15.

Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2.

Gillespie J, Ross RL, Corinaldesi C, Esteves F, Derrett-Smith E, McDermott MF, Doody GM, Denton CP, Emery P, Del Galdo F.

Arthritis Rheumatol. 2018 Jun;70(6):932-942. doi: 10.1002/art.40437. Epub 2018 Apr 23.

PMID:
29409120
16.

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G; EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.

Arthritis Res Ther. 2018 Jan 30;20(1):17. doi: 10.1186/s13075-018-1517-z.

17.

Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk.

Moreno-Moral A, Bagnati M, Koturan S, Ko JH, Fonseca C, Harmston N, Game L, Martin J, Ong V, Abraham DJ, Denton CP, Behmoaras J, Petretto E.

Ann Rheum Dis. 2018 Apr;77(4):596-601. doi: 10.1136/annrheumdis-2017-212454. Epub 2018 Jan 17.

18.

Molecular Basis for Dysregulated Activation of NKX2-5 in the Vascular Remodeling of Systemic Sclerosis.

Dritsoula A, Papaioannou I, Guerra SG, Fonseca C, Martin J, Herrick AL, Abraham DJ, Denton CP, Ponticos M.

Arthritis Rheumatol. 2018 Jun;70(6):920-931. doi: 10.1002/art.40419. Epub 2018 Apr 24.

19.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2018 Apr;77(4):563-570. doi: 10.1136/annrheumdis-2017-211912. Epub 2018 Jan 6.

20.

Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor.

Liakouli V, Elies J, El-Sherbiny YM, Scarcia M, Grant G, Abignano G, Derrett-Smith EC, Esteves F, Cipriani P, Emery P, Denton CP, Giacomelli R, Mavria G, Del Galdo F.

Ann Rheum Dis. 2018 Mar;77(3):431-440. doi: 10.1136/annrheumdis-2017-212120. Epub 2017 Dec 19.

21.

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.

Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL.

Rheumatology (Oxford). 2018 Feb 1;57(2):370-381. doi: 10.1093/rheumatology/kex410.

22.

Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis.

Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, Mageed RA.

Arthritis Rheumatol. 2018 Mar;70(3):450-461. doi: 10.1002/art.40390. Epub 2018 Feb 6.

PMID:
29193892
23.

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.

Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators.

Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242.

PMID:
29193819
24.

The Fine Line between Success and Failure in Scleroderma Lung Fibrosis Trials.

Ryerson CJ, Denton CP.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):553-554. doi: 10.1164/rccm.201711-2268ED. No abstract available.

PMID:
29186664
25.

Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis.

Allanore Y, Distler O, Matucci-Cerinic M, Denton CP.

Arthritis Rheumatol. 2018 Feb;70(2):162-170. doi: 10.1002/art.40377. Epub 2018 Jan 22. Review.

PMID:
29145709
26.

STAT3 controls COL1A2 enhancer activation cooperatively with JunB, regulates type I collagen synthesis posttranscriptionally, and is essential for lung myofibroblast differentiation.

Papaioannou I, Xu S, Denton CP, Abraham DJ, Ponticos M.

Mol Biol Cell. 2018 Jan 15;29(2):84-95. doi: 10.1091/mbc.E17-06-0342. Epub 2017 Nov 15.

27.

Editorial: Bench to Bedside-and Back Again: Finding the Goldilocks Zone Within the Scleroderma Universe.

Pope JE, Lee JJ, Denton CP.

Arthritis Rheumatol. 2018 Feb;70(2):155-156. doi: 10.1002/art.40373. Epub 2017 Dec 29. No abstract available.

PMID:
29121455
28.

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.

Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR.

J Rheumatol. 2018 Mar;45(3):405-410. doi: 10.3899/jrheum.161040. Epub 2017 Nov 1.

PMID:
29093152
29.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

PMID:
29077900
30.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

31.

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.

Mihai C, Antic M, Dobrota R, Bonderman D, Chadha-Boreham H, Coghlan JG, Denton CP, Doelberg M, Grünig E, Khanna D, McLaughlin VV, Müller-Ladner U, Pope JE, Rosenberg DM, Seibold JR, Vonk MC, Distler O.

Ann Rheum Dis. 2018 Jan;77(1):128-132. doi: 10.1136/annrheumdis-2017-211480. Epub 2017 Oct 23.

PMID:
29061853
32.

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, Matucci-Cerinic M, Denton CP, Medsger TA Jr, Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Müller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE.

Scand J Rheumatol. 2018 Jan;47(1):62-70. doi: 10.1080/03009742.2017.1299793. Epub 2017 Oct 9.

PMID:
28990485
33.

European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T.

J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1401-1424. doi: 10.1111/jdv.14458. Epub 2017 Aug 9.

PMID:
28792092
34.

European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis.

Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F, Denton CP, Rudnicka L, Frasin LA, Smith V, Gabrielli A, Aberer E, Bagot M, Bali G, Bouaziz J, Braae Olesen A, Foeldvari I, Frances C, Jalili A, Just U, Kähäri V, Kárpáti S, Kofoed K, Krasowska D, Olszewska M, Orteu C, Panelius J, Parodi A, Petit A, Quaglino P, Ranki A, Sanchez Schmidt JM, Seneschal J, Skrok A, Sticherling M, Sunderkötter C, Taieb A, Tanew A, Wolf P, Worm M, Wutte NJ, Krieg T.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1581-1594. doi: 10.1111/jdv.14466. Epub 2017 Aug 8.

PMID:
28786499
35.

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature.

Derrett-Smith EC, Martyanov V, Chighizola CB, Moinzadeh P, Campochiaro C, Khan K, Wood TA, Meroni PL, Abraham DJ, Ong VH, Lafyatis R, Whitfield ML, Denton CP.

Arthritis Res Ther. 2017 Jul 4;19(1):156. doi: 10.1186/s13075-017-1360-7.

36.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

37.

Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in pulmonary hypertension.

Schwaiger JP, Knight DS, Kaier T, Gallimore A, Denton CP, Schreiber BE, Handler C, Coghlan JG.

Echocardiography. 2017 Jun;34(6):817-824. doi: 10.1111/echo.13541. Epub 2017 Jun 13.

PMID:
28612517
38.

Scleroderma Lung Involvement, Autoantibodies, and Outcome Prediction: The Confounding Effect of Time.

Nihtyanova SI, Denton CP.

J Rheumatol. 2017 Apr;44(4):404-406. doi: 10.3899/jrheum.170055. No abstract available.

PMID:
28604345
39.

Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration.

Ahmed Abdi B, Lopez H, Karrar S, Renzoni E, Wells A, Tam A, Etomi O, Hsuan JJ, Martin GR, Shiwen X, Denton CP, Abraham D, Stratton R.

Sci Rep. 2017 Jun 1;7(1):2628. doi: 10.1038/s41598-017-02621-3.

40.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

41.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

42.

Systemic sclerosis.

Denton CP, Khanna D.

Lancet. 2017 Oct 7;390(10103):1685-1699. doi: 10.1016/S0140-6736(17)30933-9. Epub 2017 Apr 13. Review.

PMID:
28413064
43.

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.

Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML.

Genome Med. 2017 Mar 23;9(1):27. doi: 10.1186/s13073-017-0417-1.

44.

Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.

Galiè N, Denton CP, Dardi F, Manes A, Mazzanti G, Li B, Varanese L, Esler A, Harmon C, Palazzini M.

Int J Cardiol. 2017 May 15;235:67-72. doi: 10.1016/j.ijcard.2017.02.094. Epub 2017 Feb 22.

PMID:
28279499
45.

Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis.

Quillinan N, Clark KE, Youl B, Vernes J, McIntosh D, Haq S, Denton CP.

Arthritis Res Ther. 2017 Mar 7;19(1):45. doi: 10.1186/s13075-017-1252-x.

46.

Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis.

Schwaiger JP, Loder CD, Dobarro D, Kaier T, Reddecliffe S, Schreiber BE, Handler C, Denton CP, Coghlan JG.

Sci Rep. 2017 Feb 24;7:43304. doi: 10.1038/srep43304.

47.

Towards developing criteria for scleroderma renal crisis: A scoping review.

Hoa S, Stern EP, Denton CP, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group.

Autoimmun Rev. 2017 Apr;16(4):407-415. doi: 10.1016/j.autrev.2017.02.012. Epub 2017 Feb 14. Review.

PMID:
28212921
48.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2017 Jul;76(7):1207-1218. doi: 10.1136/annrheumdis-2016-210503. Epub 2017 Feb 10.

49.

Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine.

Griffin M, Ryan CM, Pathan O, Abraham D, Denton CP, Butler PE.

Stem Cell Res Ther. 2017 Feb 7;8(1):23. doi: 10.1186/s13287-016-0444-7.

50.

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

López-Isac E, Bossini-Castillo L, Palma AB, Assassi S, Mayes MD, Simeón CP, Ortego-Centeno N, Vicente E, Tolosa C, Rubio-Rivas M, Román-Ivorra JA, Beretta L, Moroncini G, Hunzelmann N, Distler JHW, Riemekasten G, de Vries-Bouwstra J, Voskuyl AE, Radstake TRDJ, Herrick A, Denton CP, Fonseca C, Martín J.

Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9. No abstract available.

Supplemental Content

Loading ...
Support Center